Chop chemotherapy of intermediate and high-grade non-hodgkin's lymphoma

Marta Llanos, Josep Tabernero, Joan Brunet, Margarita Amenedo, Cinta Pallares, Luis De Andres, Juan Jose Lopez

    Research output: Contribution to journalArticleResearchpeer-review

    6 Citations (Scopus)

    Abstract

    The results of CHOP treatment in 63 patients with intermediate and high-grade non-Hodgkin's lymphoma (Working Formulation D to I), Ann Arbor stage I to IV were analyzed. The response rate was 87% 71% complete remission and 16% partial remission with a mean duration of 22 months. The 5-year actuarial survival was 61% (95% confidence interval, 51-70% The treatment was well tolerated and no deaths due to acute toxicity were observed. Poor prognostic factors in univariate analysis were: high-grade histology, stages III and IV, B symptoms, ≥ 4 affected lymph node regions, Karnofsky index ≤70, erythrocyte sedimentation rate (ESR) <60mm, haemoglobin >100g/1 and elevated lactic dehydrogenase (LDH). Poor prognostic factors in multivariate analysis were: high-grade histology, stages III and IV, haemoglobin > 100 g/1 and elevated LDH. In summary, good results were obtained with CHOP chemotherapy, without severe toxicity. ©1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
    Original languageEnglish
    Pages (from-to)935-939
    JournalActa Oncologica
    Volume33
    Issue number8
    DOIs
    Publication statusPublished - 1 Jan 1994

    Fingerprint Dive into the research topics of 'Chop chemotherapy of intermediate and high-grade non-hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Llanos, M., Tabernero, J., Brunet, J., Amenedo, M., Pallares, C., De Andres, L., & Lopez, J. J. (1994). Chop chemotherapy of intermediate and high-grade non-hodgkin's lymphoma. Acta Oncologica, 33(8), 935-939. https://doi.org/10.3109/02841869409098460